AMY COURTNEY to Immunotherapy, Adoptive
This is a "connection" page, showing publications AMY COURTNEY has written about Immunotherapy, Adoptive.
Connection Strength
1.610
-
Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells. Clin Cancer Res. 2025 Dec 15; 31(24):5137-5144.
Score: 0.561
-
Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells. Cancer Immunol Res. 2026 Jun 02; 14(6):933-943.
Score: 0.145
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
Score: 0.141
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
Score: 0.131
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
Score: 0.130
-
Natural killer T cells and other innate-like T?lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023 02 23; 141(8):869-876.
Score: 0.115
-
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
Score: 0.093
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.091
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
Score: 0.084
-
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function. Cancer Immunol Res. 2025 Apr 02; 13(4):577-590.
Score: 0.033
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 06; 29(6):1379-1388.
Score: 0.029
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.024
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.018
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.014